Pacific Biosciences (PACB) TD Cowen 46th Annual Health Care Conference summary

Business strategy and market positioning

• Developed a comprehensive end-to-end workflow over the past five years, enabling entry into clinical markets, especially whole genome sequencing for rare diseases.

• SPARQ-Nx chemistry launching in 2026 offers improved performance, higher throughput, and significant cost reductions by enabling SMRT Cell reuse.

• Positioned as a leader in long-read sequencing, differentiating from competitors through native single-molecule sequencing and epigenetic insights.

• Avoids commoditization pressures seen in short-read sequencing, maintaining unique value and competitive pricing.

• Global expansion is a focus, with Europe and China identified as high-growth markets, while the U.S. academic segment remains challenging.

Financial performance and growth outlook

• Clinical consumables shipments grew nearly 55% last year, with clinical revenue now in the teens as a percentage of total revenue.

• Gross margins improved by 700 basis points in 2025, with guidance for an additional 100–400 basis points improvement in 2026.

• Revenue growth is expected to be driven by international markets and clinical customers, offsetting U.S. academic market weakness.

• Large-scale projects are increasing, with conversations now focused on 10,000+ sample projects and even larger opportunities.

• The clinical business is expected to become over half of total revenue within five years.

Product innovation and customer adoption

• SPARQ-Nx beta program shows 20–25% yield increase per run and consistent data quality, with full commercialization expected by early summer.

• Pricing per genome is highly competitive, dropping below $300 for large projects and potentially into the $200 range for 50,000 samples.

• Customers pay to participate in the beta, indicating strong demand and value perception.

• Utilization of Revio instruments is expected to rise from the current 20% average to the mid-to-high 20% range as project sizes grow.

• Customers require instrument redundancy, leading to multiple instrument purchases as clinical operations scale.